Sweden Current Affairs - 2020

One Million Dollar Worth Prizes created by Sweden for sustainable Food Solutions

Sweden has created 1 million USD worth prizes to feed billion of people. The prize is named as the “Food Planet Prize”. The main aim of the step is to address the climate change threats towards food supply all over the world.


The prize is to be awarded annually. Sweden is to offer two Food Planet prizes. They are “an existing scalable solution for sustainable foods” and the other includes “innovative initiatives to transform global food sector”.


Today, the world population is 7.8 billion and is expected to grow by 10 billion by 2050. In order to feed such a huge population, it is essential to transform the eating habits, reduce food waste and also improve food production.

Today there are more than 820 million people that lack sufficient food. There are many others that consume low-quality diet. The data was provided by the LANCET publication. Therefore, the prize will encourage people to work towards sustainable food production.

ETVAX: Potential Diarrhea vaccine developed in Sweden

The researchers of University of Gothenburg in Sweden have developed a potential Diarrhea vaccine candidate, named as ‘ETVAX’. This vaccine has been proved safe and effective in an early-stage clinical trial in Bangladesh. The findings were published in Science journal, The Lancet.

Key Findings

Enterotoxigenic E. coli (ETEC) bacteria are primary cause of diarrhea. At present there is no ETEC vaccine available on the market for use in children in the ETEC high-risk areas. But now, an oral ETEC vaccine candidate, named ‘ETVAX’, was developed at University of Gothenburg in collaboration with Scandinavian Biopharma, Stockholm. ETVAX consists of inactivated E. coli bacteria expressing high levels of protective antigens as well as ETEC-based B subunit protein LCTBA.

The report stated that 80% to 100% of children aged 2 to 5 years and 50% to 80% of infants aged 6 to 11 months, selected for the study responded to all key immunity generating components of vaccine. The vaccine has been proved safe and effective in an early-stage clinical trial in Bangladesh against enterotoxigenic E. coli diarrhea in children from half year (6 months) to 5 years of age.

Diarrhea leads to substantial illness and death in children in low- and middle-income countries (LMICs). As per the researchers, there is no vaccine yet for use for children and vaccine development for Diarrhea is a World Health Organization (WHO) priority.